Leap Therapeutics Reports Promising Initial Clinical Data, Updates Corporate Presentation

On January 28, 2025, Leap Therapeutics, Inc. (NASDAQ:LPTX) released significant updates regarding its recent clinical findings and corporate presentation. In a press release titled “Leap Therapeutics Reports Initial Clinical Data from Part B of DeFianCe Study and Part C of the DisTinGuish Study,” the company highlighted key insights from these studies. The press release disclosed detailed information on the clinical data, showcasing the advancements made in these research endeavors.

Part B of the DeFianCe study focused on exploring the potential of sirexatamab (DKN-01) in treating colorectal cancer. Notably, the study demonstrated a notable increase in objective response rate (ORR) by 12% when compared to the control group. Moreover, the study indicated enhanced responses in patients with high DKK1 levels, emphasizing the correlation between DKK1 and clinical benefit.

Additionally, Part C of the DisTinGuish Study emphasized the assessment of sirexatamab (DKN-01) in combination with tislelizumab and standard chemotherapy for the treatment of gastric cancer. This study revealed positive outcomes in terms of progression-free survival (PFS) and objective response rates, particularly in DKK1-high populations.

The updated corporate presentation posted on Leap Therapeutics’ website on the same day provided further insight into the potential of sirexatamab (DKN-01) in various cancer treatments, highlighting its mechanism of action and potential applications in colorectal and gastric cancers.

The company’s strategic focus appears to be on advancing into Phase 3 registrational studies, with a primary emphasis on 2nd line metastatic colorectal cancer treatments over gastric cancer therapies, aligning with the larger market opportunities in this area.

The findings from these studies indicate positive clinical benefits of sirexatamab (DKN-01) in various patient populations, especially those with genetic markers like DKK1-high and PD-L1-negative status. These outcomes also hint at potential strategic partnerships for Leap Therapeutics in the future.

Overall, Leap Therapeutics’ recent disclosures provide a comprehensive overview of promising clinical developments in cancer treatment, showcasing the company’s commitment to advancing innovative therapies in the field.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Leap Therapeutics’s 8K filing here.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.